What Is Eczema? Symptoms, Triggers, and Treatment

What Is Eczema and How Does It Develop?

Eczema (atopic dermatitis) is a chronic inflammatory skin condition caused by a combination of genetic skin barrier defects — particularly mutations in the filaggrin gene — and immune system dysregulation involving T-helper 2 cell overactivation. It affects over 31 million Americans and is part of the atopic triad alongside asthma and allergic rhinitis (Source: National Eczema Association).

Filaggrin is a structural protein essential for maintaining the integrity of the stratum corneum, the outermost layer of skin. Loss-of-function mutations in the FLG gene, found in approximately 20 to 30 percent of eczema patients in European populations, weaken the skin barrier and allow irritants, allergens, and microbes to penetrate more easily. This triggers an immune cascade dominated by T-helper 2 cells, which produce interleukins 4, 5, 13, and 31 — the key cytokines driving eczema inflammation and itch.

Environmental factors work alongside genetic predisposition to trigger and worsen eczema. Common triggers include low humidity and cold weather (which dry the skin), harsh soaps and detergents (especially sodium lauryl sulfate), fragrances in personal care products, wool and synthetic fabrics against the skin, dust mites, pet dander, pollen, certain foods (in a subset of patients), psychological stress, and sweating. Identifying individual triggers through careful observation and elimination is an important part of eczema management that the AAD emphasizes in patient education.

The prevalence of eczema has increased two to three-fold in industrialized countries over the past several decades, suggesting environmental factors play a significant role. The hygiene hypothesis proposes that reduced microbial exposure in early childhood may promote allergic immune responses. Supporting this, studies show that children raised on farms, those with older siblings, and those who attend daycare early have lower rates of atopic dermatitis. The skin microbiome also plays a role — patients with eczema often have reduced microbial diversity and are frequently colonized with Staphylococcus aureus, which exacerbates inflammation.

Filaggrin gene mutations are present in 20–30% of European eczema patients and significantly impair skin barrier function[3]

What Should You Do First to Manage Eczema?

Begin with the soak-and-seal method: take a lukewarm bath for 5 to 10 minutes, pat skin gently, then immediately apply a thick fragrance-free moisturizer within 3 minutes. For active flares, apply a low-potency topical corticosteroid like hydrocortisone 1% before moisturizing. Identify and eliminate known triggers.

The foundation of eczema management is consistent skin hydration. The American Academy of Dermatology and the British Association of Dermatologists both emphasize that daily moisturizing is the single most impactful intervention for eczema patients, regardless of disease severity. The soak-and-seal technique involves bathing in lukewarm water (not hot) for five to ten minutes, gently patting the skin until slightly damp, and immediately applying a thick moisturizer to trap water within the stratum corneum. This restores the defective skin barrier that characterizes atopic dermatitis.

Choosing the right moisturizer matters significantly. Ointments such as petroleum jelly have the highest oil content and provide the most effective barrier, but many patients find them greasy. Fragrance-free creams containing ceramides are an excellent compromise, as ceramides are a key lipid component that is deficient in eczematous skin. The National Eczema Association maintains a Seal of Acceptance program that identifies products free of common irritants. Lotions, while convenient, have the highest water content and are generally the least effective for eczema.

During active flares, moisturizing alone is usually insufficient, and topical anti-inflammatory therapy is needed. Over-the-counter hydrocortisone 1% cream or ointment is appropriate for mild flares on the body. For the face, eyelids, and skin folds, low-potency steroids should be used for limited durations, or non-steroidal alternatives like tacrolimus (Protopic) or pimecrolimus (Elidel) may be preferred. The goal is to aggressively treat flares until the skin is clear, then transition to a maintenance regimen of emollients with proactive intermittent steroid use on flare-prone areas.

AAD guidelines recommend emollient therapy as the cornerstone of atopic dermatitis management for all disease severities[1]

What Are the Symptoms of Eczema?

Eczema presents as intensely itchy, red or dark patches of dry, inflamed skin that may become thickened and scaly over time. In infants, it often appears on the cheeks and scalp. In children and adults, it commonly affects the inside of elbows, behind the knees, hands, wrists, and neck. Scratching leads to excoriation and possible infection.

The hallmark symptom of atopic dermatitis is pruritus — intense itching that is often described as the most debilitating aspect of the disease. The itch frequently precedes visible skin changes and creates a vicious itch-scratch cycle: scratching damages the skin barrier, triggers more inflammation, and increases itchiness. Studies published in the Journal of Investigative Dermatology have shown that eczema itch involves both histamine-dependent and histamine-independent pathways, which explains why antihistamines provide only partial relief for many patients.

The appearance of eczema varies by age, skin tone, and chronicity. In infants, it typically appears as oozing, crusted patches on the cheeks, forehead, and scalp. In children and adults, it migrates to flexural areas — the inner elbows, behind the knees, wrists, and neck. On lighter skin, eczema appears red and inflamed. On darker skin tones, it may appear dark brown, purple, or gray, and post-inflammatory hyperpigmentation is more pronounced. Chronic eczema leads to lichenification — thickened, leathery skin with exaggerated skin lines.

Eczema can significantly impact quality of life. Studies show that moderate-to-severe eczema has a quality-of-life burden comparable to diabetes, heart disease, and depression. Sleep disruption from nighttime itching is extremely common, affecting up to 60 percent of children with eczema and their parents. The psychological impact includes anxiety, depression, social isolation, and in children, difficulty concentrating at school. The National Eczema Association reports that adults with eczema miss an average of several work days per year due to flares.

Research shows the quality-of-life burden of moderate-to-severe eczema is comparable to major chronic diseases[2]

How Do Topical Corticosteroids Work for Eczema?

Topical corticosteroids suppress inflammation by inhibiting pro-inflammatory cytokines, reducing immune cell activity, and constricting blood vessels in the skin. They are classified into seven potency groups, from mild (hydrocortisone 1%) to super-potent (clobetasol 0.05%). The AAD recommends matching potency to disease severity, body location, and patient age.

Topical corticosteroids have been the backbone of eczema treatment for over 60 years and remain the most effective anti-inflammatory agents available for flare management. They work by binding to intracellular glucocorticoid receptors, suppressing the transcription of pro-inflammatory genes including those encoding interleukins, prostaglandins, and leukotrienes. This rapidly reduces redness, swelling, itching, and the urge to scratch. The AAD guidelines recommend using an appropriate-strength steroid applied once or twice daily during flares until the skin is completely clear.

Steroid phobia — an irrational fear of using topical corticosteroids — is one of the most significant barriers to effective eczema treatment. Studies have shown that up to 80 percent of eczema patients or their parents express concern about steroid side effects, often leading to underuse, treatment failure, and unnecessary suffering. While side effects such as skin atrophy, telangiectasia, and striae can occur, they are associated with prolonged, unsupervised use of potent steroids on thin-skinned areas, not with appropriate short-term flare management. The BAD has published guidelines specifically addressing steroid phobia.

A proactive maintenance strategy using intermittent topical corticosteroids can prevent eczema flares before they start. The approach involves applying a mid-potency steroid twice weekly to areas that have previously flared, even when the skin appears clear. A randomized controlled trial in the New England Journal of Medicine demonstrated that this proactive approach reduced eczema relapses by 60 to 70 percent compared with reactive treatment alone. This strategy is now recommended by both the AAD and European Academy of Dermatology and Venereology.

A landmark NEJM trial showed proactive intermittent steroid use reduced eczema relapses by 60–70%[4]

What Non-Steroidal Treatments Are Available for Eczema?

Non-steroidal topical options include calcineurin inhibitors (tacrolimus and pimecrolimus), the PDE4 inhibitor crisaborole (Eucrisa), and the JAK inhibitor ruxolitinib (Opzelura). These are especially useful for sensitive areas like the face and eyelids where long-term steroid use is discouraged, and for patients who prefer steroid-free maintenance therapy.

Topical calcineurin inhibitors — tacrolimus 0.03% and 0.1% ointment (Protopic) and pimecrolimus 1% cream (Elidel) — suppress T-cell activation without the skin-thinning effects of corticosteroids. They are FDA-approved for moderate-to-severe (tacrolimus) and mild-to-moderate (pimecrolimus) atopic dermatitis in patients aged 2 and older. These agents are particularly valuable for the face, eyelids, neck, and genital area where steroid atrophy is a concern. A common side effect is a burning or stinging sensation upon application that typically diminishes with continued use over one to two weeks.

Crisaborole 2% ointment (Eucrisa) is a phosphodiesterase 4 (PDE4) inhibitor approved for mild-to-moderate eczema in patients aged 3 months and older. By inhibiting PDE4, it reduces the breakdown of cyclic adenosine monophosphate (cAMP), which leads to decreased production of pro-inflammatory cytokines. Clinical trials demonstrated statistically significant improvement in disease severity compared with vehicle, though some dermatologists consider its efficacy more modest than calcineurin inhibitors. It is well-tolerated, with application site burning being the most common adverse effect.

Ruxolitinib 1.5% cream (Opzelura), a topical Janus kinase (JAK) inhibitor approved in 2021, represents the newest class of non-steroidal topical eczema treatment. JAK inhibitors block the intracellular signaling pathways of multiple inflammatory cytokines simultaneously, providing rapid itch relief often within 24 to 48 hours. Phase 3 trials (TRuE-AD1 and TRuE-AD2) showed that ruxolitinib cream achieved significantly greater eczema clearance than vehicle, with efficacy comparable to mid-potency topical corticosteroids. It is approved for mild-to-moderate atopic dermatitis in non-immunocompromised patients aged 12 and older.

Phase 3 TRuE-AD trials demonstrated ruxolitinib cream achieved eczema clearance comparable to mid-potency corticosteroids[5]

How Has Dupilumab Changed Severe Eczema Treatment?

Dupilumab (Dupixent) is a monoclonal antibody that blocks interleukin-4 and interleukin-13 signaling, the key drivers of type 2 inflammation in eczema. FDA-approved for moderate-to-severe atopic dermatitis, it has demonstrated 70% or greater improvement in over half of treated patients in clinical trials, fundamentally transforming outcomes for those who failed conventional therapies.

Before dupilumab's approval in 2017, patients with severe atopic dermatitis who failed topical therapies had limited systemic options — primarily immunosuppressants like cyclosporine, methotrexate, azathioprine, and mycophenolate mofetil, all of which carry significant toxicity risks with long-term use. Dupilumab changed this landscape by offering a targeted biologic therapy with a favorable safety profile. Administered as a subcutaneous injection every two weeks after a loading dose, it specifically blocks the shared receptor component for IL-4 and IL-13, the central cytokines of the type 2 immune response.

The pivotal SOLO 1 and SOLO 2 trials published in the New England Journal of Medicine demonstrated that dupilumab monotherapy achieved a 75% or greater reduction in eczema severity (EASI-75) in approximately 44 to 51 percent of patients at 16 weeks, compared with 12 to 15 percent for placebo. Itch reduction was equally dramatic, with significant improvement in pruritus scores within the first two weeks. Long-term extension studies have confirmed that these benefits are sustained for up to three years with continued treatment, and the safety profile remains favorable.

Dupilumab is now approved for moderate-to-severe atopic dermatitis in adults and children aged 6 months and older, as well as for moderate-to-severe asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and prurigo nodularis. The most common side effect is conjunctivitis, occurring in approximately 10 to 15 percent of patients, which is managable with eye drops. Unlike traditional immunosuppressants, dupilumab does not increase the risk of serious infections, does not require routine blood monitoring, and carries no known risk of malignancy, making it suitable for long-term use.

SOLO 1 and SOLO 2 pivotal trials showed dupilumab achieved EASI-75 in 44–51% of patients vs. 12–15% placebo at 16 weeks[6]

How Can You Identify and Avoid Eczema Triggers?

Keep a symptom diary to track flares alongside potential triggers including weather changes, stress, specific products, and foods. Common environmental triggers include low humidity, harsh detergents, fragrances, wool clothing, dust mites, and pet dander. Eliminating triggers alongside consistent moisturizing can significantly reduce flare frequency and severity.

Environmental control is a critical component of eczema management that complements medical therapy. The National Institute for Health and Care Excellence (NICE) guidelines recommend that all eczema patients receive education about trigger avoidance. Practical steps include using fragrance-free soaps and detergents, wearing soft cotton clothing rather than wool or synthetic fabrics, maintaining indoor humidity between 40 and 60 percent using a humidifier during dry months, and keeping room temperatures moderate to avoid excessive sweating.

Dust mite allergy is common in eczema patients, and several studies have demonstrated that dust mite reduction measures can improve eczema symptoms. Practical strategies include encasing mattresses and pillows in dust-mite-proof covers, washing bedding weekly in water at 130 degrees Fahrenheit or higher, removing carpeting from bedrooms, and using a HEPA-filter vacuum. A meta-analysis in Clinical and Experimental Allergy found that dust mite reduction measures produced modest but statistically significant improvements in eczema severity scores.

Stress is a well-documented eczema trigger that operates through neuroimmune pathways. The hypothalamic-pituitary-adrenal axis releases cortisol and neuropeptides including substance P that can directly activate mast cells and exacerbate type 2 inflammation. Psychological interventions including cognitive behavioral therapy, mindfulness-based stress reduction, and habit reversal training for scratch reduction have shown benefit in clinical trials. The National Eczema Association recommends stress management as part of a comprehensive eczema management plan alongside medical treatment.

A meta-analysis found dust mite reduction measures produced statistically significant improvement in eczema severity[7]

What Is Wet Wrap Therapy for Eczema?

Wet wrap therapy involves applying topical medication and moisturizer to the skin, then covering with a damp layer of cotton fabric (or gauze) followed by a dry outer layer. It enhances medication absorption, provides intense hydration, and physically prevents scratching. The AAD recommends it for severe flares under medical supervision.

Wet wrap therapy is an intensive treatment technique used to manage severe eczema flares, particularly in children. The procedure begins with a lukewarm soak, followed by application of topical corticosteroid (usually diluted to reduce potency) or emollient to affected areas. A layer of damp cotton clothing or tubular bandages is then applied over the medication, followed by a dry outer layer. The wraps are typically left in place for two to six hours or overnight. Studies published in the Journal of Allergy and Clinical Immunology have shown that wet wraps can reduce eczema severity by 50 to 70 percent within one to two weeks.

The mechanism of wet wrap therapy is multifactorial. The occlusive damp layer increases the absorption of topical medications by enhancing skin hydration and drug penetration through the stratum corneum. The cooling effect of evaporation provides immediate itch relief. The physical barrier prevents scratching, which is particularly valuable at night when patients are most likely to scratch unconsciously. A study in the British Journal of Dermatology demonstrated that wet wraps with dilute corticosteroids were as effective as wet wraps with potent steroids, supporting the use of diluted preparations for safety.

Wet wrap therapy should be initiated under medical guidance, especially when corticosteroids are used. Over-occlusion of potent steroids can increase systemic absorption and skin atrophy risk. The AAD recommends wet wrap therapy courses of up to 14 days during severe flares rather than continuous long-term use. For children, parents should be trained by a dermatology nurse or clinician. Commercially available tubular bandages and specialized eczema suits have made home application more practical and consistent than improvised wraps.

Clinical studies show wet wrap therapy can reduce eczema severity by 50–70% within one to two weeks[8]

How Does Eczema Affect Children Differently?

Eczema affects approximately 13 percent of children in the United States, with onset typically before age 5. In infants, it usually appears on the face and scalp. Childhood eczema increases the risk of developing asthma and allergic rhinitis through the atopic march. Approximately 60 to 70 percent of children see significant improvement by adolescence.

The atopic march describes the natural progression from eczema in infancy to food allergies, asthma, and allergic rhinitis in later childhood and adolescence. Research suggests that the disrupted skin barrier in eczema allows allergens to penetrate the skin and sensitize the immune system, priming it for allergic responses in other organ systems. A large prospective study in the Journal of Allergy and Clinical Immunology found that early-onset severe eczema was the strongest predictor of subsequent asthma development, particularly when combined with early food sensitization.

Treatment of childhood eczema follows the same principles as adult management but with important age-specific considerations. Emollient therapy should be instituted early and aggressively — the AAD recommends applying moisturizer at least twice daily and after every bath. For topical corticosteroids, lower-potency preparations are preferred, especially for infants and for application to the face and diaper area. Tacrolimus 0.03% and pimecrolimus are approved for children aged 2 and older as steroid-sparing alternatives. Dupilumab is now FDA-approved for children as young as 6 months with moderate-to-severe atopic dermatitis.

The BEEP trial (Barrier Enhancement for Eczema Prevention), a landmark randomized controlled trial, investigated whether daily emollient application from birth could prevent eczema in high-risk infants. While the initial results did not show a statistically significant reduction in eczema incidence at age 2, the study highlighted the importance of skin barrier care in early life. Ongoing research is exploring whether early intervention with emollients combined with microbial or immunological approaches can break the atopic march and prevent the cascade of allergic diseases.

A large prospective study identified early-onset severe eczema as the strongest predictor of subsequent asthma development[9]

What Emerging Therapies Are Available for Eczema?

Beyond dupilumab, several new therapies are expanding eczema treatment options. Oral JAK inhibitors abrocitinib (Cibinqo) and upadacitinib (Rinvoq) offer rapid itch relief within days. Tralokinumab (Adbry) targets IL-13 specifically. Additional biologics and topical agents targeting the type 2 inflammatory pathway are in late-stage clinical development.

Oral JAK inhibitors represent a significant therapeutic advance for moderate-to-severe atopic dermatitis. Abrocitinib (Cibinqo, JAK1 selective) and upadacitinib (Rinvoq, JAK1 selective) are both FDA-approved for adults with moderate-to-severe eczema who failed conventional therapy. In head-to-head trials, upadacitinib 30 mg achieved numerically higher response rates than dupilumab at 16 weeks, with the added advantage of oral dosing and faster onset of itch relief, often within one to two days. However, JAK inhibitors carry boxed warnings about cardiovascular events, malignancy, and thrombosis based on class data from rheumatoid arthritis studies.

Tralokinumab (Adbry) is a monoclonal antibody that specifically neutralizes interleukin-13, distinguishing it from dupilumab which blocks both IL-4 and IL-13. Phase 3 ECZTRA trials demonstrated significant efficacy for moderate-to-severe atopic dermatitis, with approximately 33 to 38 percent of patients achieving clear or almost clear skin at 16 weeks as monotherapy. Tralokinumab is administered by subcutaneous injection every two weeks after a loading period. Its more targeted mechanism may result in a different side effect profile, with lower rates of conjunctivitis compared to dupilumab in cross-trial comparisons.

The pipeline for eczema therapeutics continues to expand rapidly. Nemolizumab (anti-IL-31 receptor antibody) targets the primary itch cytokine and has shown dramatic pruritus reduction in Phase 3 trials. Lebrikizumab (another anti-IL-13 antibody) has demonstrated strong Phase 3 efficacy data. Topical agents in development include tapinarof (an aryl hydrocarbon receptor agonist already approved for psoriasis) and several topical JAK inhibitors beyond ruxolitinib. This growing therapeutic landscape means that dermatologists can increasingly tailor treatment to individual patient profiles and preferences.

Head-to-head trials showed upadacitinib achieved numerically higher response rates than dupilumab at 16 weeks[10]

What Are the Complications if Eczema Is Left Untreated?

Untreated eczema can lead to secondary bacterial skin infections (particularly Staphylococcus aureus), chronic sleep disruption, worsening of the itch-scratch cycle causing permanent skin thickening, progression of the atopic march toward asthma and allergic rhinitis, and significant psychological distress including depression and anxiety.

The most immediate complication of untreated eczema is secondary bacterial infection. Staphylococcus aureus colonizes the skin of over 90 percent of eczema patients, and scratching introduces bacteria through breaks in the skin barrier [3]. Infected eczema appears as oozing, crusting, or pustules and may require oral antibiotics in addition to eczema treatment. Eczema herpeticum — a widespread herpes simplex virus infection of eczematous skin — is a dermatologic emergency requiring antiviral therapy.

Chronic untreated eczema perpetuates the itch-scratch cycle, leading to lichenification — permanent thickening and darkening of the skin. This cycle also causes significant sleep disruption, which has cascading effects on immune function, mood, cognitive performance, and quality of life. Studies show that children with poorly controlled eczema experience learning difficulties and behavioral problems comparable to those seen in children with chronic pain conditions [2].

With proper treatment — consistent moisturizing, appropriate use of topical anti-inflammatories, and trigger avoidance — most people with eczema can achieve excellent disease control and prevent the vast majority of these complications.

Staphylococcus aureus colonizes the skin of over 90% of eczema patients[3]

• Secondary bacterial infections: Staphylococcus aureus colonization leading to impetigo and cellulitis
• Chronic sleep disruption: affecting up to 60% of eczema patients, causing fatigue and impaired concentration
• Lichenification: permanent skin thickening from chronic scratching and inflammation
• Atopic march: progression from eczema to allergic rhinitis and asthma, especially in children
• Depression and anxiety: moderate-to-severe eczema has quality-of-life burden comparable to major chronic diseases
• [Rare] Eczema herpeticum: widespread herpes simplex infection of eczematous skin requiring emergency antiviral treatment

How Can You Live Well With Eczema?

Living well with eczema means building daily habits around skin care, trigger avoidance, sleep hygiene, stress management, and emotional health. With consistent treatment and lifestyle adjustments, most people with eczema can significantly reduce flare frequency and enjoy a full, active lifestyle.

Make moisturizing a non-negotiable part of your daily routine, ideally applying a thick fragrance-free cream or ointment at least twice daily and within 3 minutes of every bath or shower. Keep travel-sized moisturizer in your bag, at your desk, and in your car so you can reapply whenever skin feels dry. Choose cotton or bamboo clothing next to your skin, wash new clothes before wearing to remove residual chemicals, and use fragrance-free laundry detergent with an extra rinse cycle.

Sleep quality is often severely impacted by eczema itch, which tends to worsen at night. Keep your bedroom cool (65-68 degrees Fahrenheit), use cotton sheets, and consider wearing cotton gloves to bed to minimize scratch damage. Apply moisturizer and any prescribed topical medications right before bed. Some dermatologists recommend a non-sedating antihistamine during severe flares, though evidence for itch relief is limited since eczema itch involves non-histamine pathways.

The emotional burden of eczema is real and deserves attention. If eczema is affecting your self-esteem, social life, or mental health, talk to your dermatologist. The National Eczema Association offers support groups, educational resources, and community forums. Cognitive behavioral therapy has demonstrated benefit for the psychological distress and habit reversal associated with eczema. Remember that eczema is a medical condition, not a reflection of hygiene, and effective treatments exist even for severe cases.

What Questions Should You Ask Your Doctor About Eczema?

Preparing specific questions before your dermatology appointment helps you get a clear management plan and set realistic expectations for your eczema treatment. Here are the most important questions to bring, along with why each one matters.

Understanding your specific eczema severity, triggers, and treatment options empowers you to take an active role in your care. Write down your questions before your visit and do not hesitate to ask your dermatologist to clarify anything you do not fully understand.

• What severity level is my eczema, and what does that mean for treatment? -- Severity determines whether topical treatment alone is sufficient or systemic therapy should be considered
• Which specific moisturizers and cleansers do you recommend for my skin? -- Not all products labeled 'for sensitive skin' are appropriate for eczema; your dermatologist can recommend specific formulations
• How should I use topical steroids safely to avoid skin thinning? -- Understanding proper application, duration, and body-site considerations prevents steroid phobia and ensures effective treatment
• Should I be tested for food or environmental allergies? -- Allergy testing is warranted for moderate-to-severe eczema in young children but unnecessary for most adults
• Am I a candidate for biologic therapy like dupilumab? -- If conventional treatments are not controlling your eczema, newer targeted therapies may offer significant improvement
• How can I prevent my child from developing asthma given their eczema? -- The atopic march is a real concern, and early aggressive eczema treatment may help reduce asthma risk